share_log

AstraZeneca | 6-K: Voydeya Approved in the Us as Add-On Therapy to Ravulizumab or Eculizumab for Treatment of Extravascular Haemolysis in Adults with the Rare Disease PNH

SEC announcement ·  Apr 2 08:49
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more